Market-Moving News for June 4th
$ANNX
$AX
$VKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Savings Institutions
Finance
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 12/23/2025 | $16.00 | Buy | Chardan Capital Markets | |
| 10/29/2025 | $106.00 | Buy | Canaccord Genuity | |
| 5/21/2025 | $90.00 | Buy | Jefferies | |
| 4/29/2025 | $104.00 | Overweight | Cantor Fitzgerald | |
| 4/8/2025 | $30.00 | Neutral | Goldman | |
| 2/13/2025 | $102.00 | Sector Outperform | Scotiabank | |
| 2/7/2025 | $38.00 | Neutral | Citigroup | |
| 12/2/2024 | Overweight | Piper Sandler |
144 - Axos Financial, Inc. (0001299709) (Subject)
SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)
8-K - Axos Financial, Inc. (0001299709) (Filer)
Chardan Capital Markets initiated coverage of Annexon with a rating of Buy and set a new price target of $16.00
Canaccord Genuity initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $106.00
Jefferies initiated coverage of Axos Financial with a rating of Buy and set a new price target of $90.00
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.
Axos Bank, the nationwide bank subsidiary of Axos Financial, Inc. (NYSE:AX), and Priority Rollfi, a subsidiary of Priority Technology Holdings, Inc., (NASDAQ:PRTH), today announced a new partnership following a competitive RFP process. Rollfi was selected to supply its embedded and white-label payroll and benefits technology infrastructure to enhance Axos's business banking platform. Through this collaboration, Axos Bank will integrate Rollfi's modular, API-based technology to automate payroll processing, streamline tax compliance, and deliver connected employee benefits management. These capabilities will be embedded directly within Axos's digital banking ecosystem, enabling commercial b
Axos Financial, Inc. (NYSE:AX) ("Axos" or the "Company") today announced unaudited financial results for the second fiscal quarter ended December 31, 2025. Net income was $128.4 million and diluted earnings per share ("EPS") was $2.22 for the quarter ended December 31, 2025. Net income for the quarter ended December 31, 2024 was $104.7 million and diluted EPS was $1.80. Adjusted earnings and adjusted earnings per diluted common share ("Adjusted EPS"), non-GAAP measures described further below, increased $24.3 million to $130.2 million and increased $0.43 to $2.25, respectively, for the quarter ended December 31, 2025, compared to $105.8 million and $1.82, respectively, for the quarter ended
4 - Axos Financial, Inc. (0001299709) (Issuer)
4 - Axos Financial, Inc. (0001299709) (Issuer)
4 - Axos Financial, Inc. (0001299709) (Issuer)
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.
Axos Financial, Inc. (NYSE:AX) ("Axos" or the "Company") today announced unaudited financial results for the second fiscal quarter ended December 31, 2025. Net income was $128.4 million and diluted earnings per share ("EPS") was $2.22 for the quarter ended December 31, 2025. Net income for the quarter ended December 31, 2024 was $104.7 million and diluted EPS was $1.80. Adjusted earnings and adjusted earnings per diluted common share ("Adjusted EPS"), non-GAAP measures described further below, increased $24.3 million to $130.2 million and increased $0.43 to $2.25, respectively, for the quarter ended December 31, 2025, compared to $105.8 million and $1.82, respectively, for the quarter ended
Axos Financial, Inc. (NYSE:AX) ("Axos" or the "Company"), holding company for Axos Bank, Axos Clearing LLC, and Axos Invest, Inc., announced today that it will host a conference call on Thursday, January 29, 2026 at 5:00 PM ET (2:00 PM PT) to discuss financial results for the second quarter of fiscal year 2026 ended December 31, 2025. Executive management will discuss the Company's second quarter fiscal 2026 results on the call. The Company plans to distribute its earnings results on Thursday, January 29, 2026 after 4:00 PM ET (1:00 PM PT). Interested parties may access the live conference call by visiting Axos Financial's website at http://investors.axosfinancial.com and clicking on th
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.
Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Exposure Exceeded Target Concentration in Fasted Patients; Evaluation in Relation to Food Intake Ongoing in Proof-of-Concept CAD Study, Update Expected by Year-end 2025 $227 Million i
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-medi
SC 13G/A - Annexon, Inc. (0001528115) (Subject)
SC 13G/A - Annexon, Inc. (0001528115) (Subject)
SC 13G/A - Annexon, Inc. (0001528115) (Subject)